Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
DenmarkIPO:
30 April 1981Website:
http://www.novonordisk.comNext earnings report:
06 November 2024Last dividends:
16 August 2024Next dividends:
N/APrice
after hours | Fri, 27 Sep 2024 23:59:59 GMTAnalysts recommendations
Institutional Ownership
NVO Latest News
It's in Novo Nordisk's best interest to produce more winning cardiometabolic drugs. To that end, it's inking collaboration deals with multiple early-stage biotechs.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity.
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies.
VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to provide a video update on the Company's highly prospective Belltopper Gold Project (“Belltopper”), following the Company's recent announcement titled “Belltopper Mineralisation Modelling Defines Prospectivity” released to the ASX on 25 September 2024 (“Belltopper Announcement”).
Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.
CNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.
Novo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result.
The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant's blockbuster drugs Ozempic and Wegovy.
U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,000 a month.
What type of business is Novo Nordisk A/S?
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S is in the Healthcare sector
What industry is Novo Nordisk A/S in?
Novo Nordisk A/S is in the Biotechnology industry
What country is Novo Nordisk A/S from?
Novo Nordisk A/S is headquartered in Denmark
When did Novo Nordisk A/S go public?
Novo Nordisk A/S initial public offering (IPO) was on 30 April 1981
What is Novo Nordisk A/S website?
https://www.novonordisk.com
Is Novo Nordisk A/S in the S&P 500?
No, Novo Nordisk A/S is not included in the S&P 500 index
Is Novo Nordisk A/S in the NASDAQ 100?
No, Novo Nordisk A/S is not included in the NASDAQ 100 index
Is Novo Nordisk A/S in the Dow Jones?
No, Novo Nordisk A/S is not included in the Dow Jones index
When was Novo Nordisk A/S the previous earnings report?
No data
When does Novo Nordisk A/S earnings report?
The next expected earnings date for Novo Nordisk A/S is 06 November 2024